EBS News and Press, Emergent Biosolutions Inc. From 02/20/20

Emergent Biosolutions (NYSE: EBS ): Q4 Non-GAAP EPS of $1.57 beats by $0.70 ; GAAP EPS of $0.89 beats by $0.02 . More news on: Emergent BioSolutions Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

GAITHERSBURG, Md., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2019. FINANCIAL HIGHLIGHTS Q4 2019 AND RECENT BUSINESS ACCOMPLISHMENTS Awarded a contract by the Office of the A...

GAITHERSBURG, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2019, recent business developments, financia...

GAITHERSBURG, Md., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for the approval of the company’s single-dose or...

January 21, 2020 FN Media Group Presents USA News Group Market Commentary Los Angeles, CA – January 21, 2020 – USA News Group – Officials report that passengers from Wuhan, China are now being screened at J.F.K. New York, San Francisco and Los Angeles airpo...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this Read more ...

A new study published in the journal Molecular Therapy reports that researchers found a drug used in the treatment of HIV that may also suppress Zika virus infection. Zika virus disease is caused by a virus transmitted primarily by Aedes mosquitoes, which bite during the day. Research and d...

Emergent BioSolutions (NYSE: EBS ) has received agreement from the European Medicines Agency (EMA) to pursue the proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. More news on: Emergent BioSolutions Inc., Healthcare stocks news, Re...

Emergent BioSolutions (NYSE: EBS ) reports FY19 prelim revenue in the range of $1.1B-$1.5B against prior guidance of $1.06B-$1.14B, consensus estimate of $1.1B. More news on: Emergent BioSolutions Inc., Healthcare stocks news, Read more ...

GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. T...